Cyanotech

CYAN · OTC

$0.6564−$0.0436 (−6.23%)TodayMarket closed ·
Prev close $0.70

About CYAN

Cyanotech Corp. engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. The company is headquartered in Kailua Kona, Hawaii and currently employs 83 full-time employees. The Company, through its microalgae technology, produces BioAstin Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica. Its BioAstin Hawaiian Astaxanthin offers antioxidant activity which supports skin, eye and joint health, as well as recovery from exercise. Hawaiian Spirulina Pacifica is a nutrient-rich superfood dietary supplement clinically supported for natural energy, immune system support, cardiovascular health and as a concentrated source of protein, antioxidant carotenoids, and essential nutrients. Its products are produced from microalgae grown at its 96-acre facility in Kona, Hawaii. The company sells its products direct to consumers at retail locations in the United States and online at www.nutrex-hawaii.com and also distributes to dietary supplement, nutraceutical and cosmeceutical manufacturers and marketers.

Employees
83
Headquarters
KAILUA KONA, Hawaii
Listed
May 21, 1999
Sector
Consumer Staples
Industry
Personal Care Products

CYAN key statistics

Market cap
4.85M
Price-earnings ratio
—
Dividend yield
—
Average volume
11.42K
Volume
350
Open price
$0.7199
High today
$0.7199
Low today
$0.6564
52 Week high
$0.782
52 Week low
$0.00

Cyanotech (CYAN) at a glance

Cyanotech (CYAN) last traded at $0.6564, with a market cap of 4.85M.

Today the stock has traded between $0.6564 and $0.7199. The current price is 0.0% above the day's low and 8.8% below its high.

Volume so far is 350 shares, below the average of 11.42K shares a day.

Over the past year Cyanotech has ranged from $0.00 to $0.782, and now sits 84% of the way up that range.

Cyanotech met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q1 FY26 it reported -$0.13 per share against an estimate of $0.00.

CYAN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 49.0% on average.

  1. Q4 FY02: reported -$0.16 per share against an estimate of -$0.0816
  2. Q1 FY03: reported -$0.20 per share against an estimate of -$0.204
  3. Q3 FY05: reported $0.08 per share against an estimate of $0.0408
  4. Q4 FY05: reported $0.00 per share against an estimate of $0.0816
  5. Q2 FY06: reported -$0.08 per share against an estimate of $0.0816
  6. Q3 FY24: reported -$0.16 per share against an estimate of $0.00
  7. Q1 FY25: reported -$0.17 per share against an estimate of $0.00
  8. Q1 FY26: reported -$0.13 per share against an estimate of $0.00

CYAN news

  • Press releaseBusiness Wire

    Cyanotech Reports Financial Results for the Second Quarter of Fiscal 2026

  • Press releaseBusiness Wire

    Cyanotech Reports Financial Results for the First Quarter of Fiscal 2026

  • Press releaseBusiness Wire

    Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2025

  • Press releaseBusiness Wire

    Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2025

  • Press releaseBusiness Wire

    Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2025

  • Avi Kapoor

    $1.7M Bet On Standard BioTools? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying

  • Press releaseBusiness Wire

    Cyanotech Reports Financial Results for the First Quarter of Fiscal 2025

  • Avi Kapoor

    Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying

Similar companies

Companies in the same industry as Cyanotech

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.